A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator- Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: Pembrolizumab
V940 (mRNA-4157)/ Placebo
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Dr. Giuseppe Lo Russo
This trial is testing the treatment V940 (mRNA-4157) administered in combination with pembrolizumab (V940 plus pembrolizumab) in people undergoing surgery to remove non-small cell lung cancer (NSCLC).
This trial will compare:
- V940 plus pembrolizumab
- Placebo plus pembrolizumab, both administered after surgery and chemotherapy.
All participants will then receive pembrolizumab.
V940 is a type of personalised treatment that uses the tumour's genes to teach the immune system to fight it.
Last update: 20/05/2025